A Reversal for Organovo Holdings Inc Is Not Near. The Stock Declines Again

Share with your friends


The stock of Organovo Holdings Inc (NYSEMKT:ONVO) is a huge mover today! The stock is down 2.97% or $0.09 after the news, hitting $2.94 per share. About 515,204 shares traded hands. Organovo Holdings Inc (NYSEMKT:ONVO) has declined 35.81% since April 16, 2015 and is downtrending. It has underperformed by 33.27% the S&P500.
The move comes after 5 months negative chart setup for the $277.19 million company. It was reported on Nov, 18 by Barchart.com. We have $2.56 PT which if reached, will make NYSEMKT:ONVO worth $36.03 million less.

According to Zacks, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.”

The institutional sentiment increased to 2.15 in Q2 2015. Its up 1.13, from 1.02 in 2015Q1. The ratio increased, as 16 funds sold all Organovo Holdings Inc shares owned while 17 reduced positions. 30 funds bought stakes while 41 increased positions. They now own 23.43 million shares or 18.91% more from 19.71 million shares in 2015Q1.

Penbrook Management Llc holds 0.62% of its portfolio in Organovo Holdings Inc for 174,500 shares. Bolton Lp owns 246,800 shares or 0.26% of their US portfolio. Moreover, Messner & Smith Theme Value Investment Management Ltd Ca has 0.19% invested in the company for 36,990 shares. The Virginia-based Strategic Investment Management Llc has invested 0.19% in the stock. Cue Financial Group Inc., a Arizona-based fund reported 36,000 shares.

Since September 23, 2015, the stock had 0 insider purchases, and 1 sale for $24,193 net activity. Baltera Robert Jr. sold 6,000 shares worth $24,193.

Organovo Holdings Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Add Comment